Skip to Content

Novo Nordisk A/S Class B NOVO B Stock Quote

| Rating as of


Market Closed

| Currency in DKK

  • Last Close 643.90
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Large Growth
  • Day Range 642.40  –  656.00
  • Year Range 379.10  –  690.30
  • Market Cap 2.8800 Tril
  • Volume / Avg 3.4 Mil /  2.9 Mil
  • Price / Sales 14.45
  • Price / Book 31.90
  • Forward Div Yield 1.16%
  • Trailing Div Yield 1.46%

Morningstar‘s Stock Analysis NOVO B

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Biopharma Industry: Medicare Drug Price Negotiation Impact Reduced by Expected Generic Pressures

Damien Conover Sector Director

Analyst Note

| Damien Conover |

As part of the Inflation Reduction Act, the U.S. Department of Health and Human Services on Aug. 29 announced the first 10 drugs selected for mandated 2026 Medicare price negotiations. This doesn’t have a major impact on our valuations or moat ratings for the biopharma industry. The 10 drugs have been on the market for a prolonged period (seven years for small-molecule drugs and 11 years for biologics) and were selected based on the largest gross (before discounts) spending in Medicare Part D.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics NOVO B

Company Profile NOVO B

Business Description

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Alle 1
Bagsvaerd, DK-2880, DNK
Industry Biotechnology
Employees 59,337

Related Articles NOVO B

Competitors & Peers NOVO B

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of NOVO B’s competitive advantage.

Novo Nordisk A/S Class B


Eli Lilly and Co


AstraZeneca PLC


Sanofi SA

−$7.60 (1.17%) −$7.32 (1.34%) +$96.00 (0.87%) +$0.72 (0.71%)
Market Cap
2.88 Tril509.89 Bil17.21 Tril127.22 Bil
Biotechnology Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Novo Nordisk A/S Class B Stock

Yes. NOVO B has a forward dividend yield of 1.10%. See NOVO B’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

NOVO B’s market cap is 2.88 Tril.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

NOVO B’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

NOVO B’s price/sales is 14.45.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

NOVO B’s price/forward earnings is 43.26.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

NOVO B’s price/book is 31.90.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See NOVO B’s valuation ratios compared to the Market Index.

NOVO B’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare NOVO B’s historical performance against its industry peers and the overall market.